Recent Tech Transfer Deals, May 2013
This article was originally published in Start Up
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on licensing agreements between universities or other research institutions and biopharma, medtech, and diagnostic start-ups.
You may also be interested in...
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.
Two $1bn+ alliances were penned in October. Financing reached $7.7bn in biopharma, $636m in device, and $140m in diagnostics.
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.